18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

被引：23

作者：

Ansquer, Catherine ^{[1
]}

Hervouet, Thomas ^{[2
]}

Devillers, Anne ^{[2
]}

de Guibert, Sophie ^{[3
]}

Gastinne, Thomas ^{[4
]}

Le Gouill, Steven ^{[4
]}

Garin, Etienne ^{[2
]}

Moreau, Anne ^{[5
]}

Kraeber-Bodere, Francoise ^{[1
]}

Lamy, Thierry ^{[3
]}

机构：

[1] CHU Nantes, Dept Med Nucl, Nantes, France

[2] Ctr Eugene Marquis, Dept Med Nucl, Rennes, France

[3] CHU Rennes, Serv Hematol Clin, Hop Pontchaillou, F-35033 Rennes, France

[4] CHU Nantes, Serv Hematol Clin, Hop Hotel Dieu, Rennes, France

[5] CHU Nantes, Lab Anat Pathol, Hop Hotel Dieu, Rennes, France

来源：

HAEMATOLOGICA | 2007年 / 93卷 / 01期

关键词：

18F FDG-PET; FDG-PET/CT; lymphocyte-predominant Hodgkin's disease; staging;

D O I：

10.3324/haematol.11661

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This bicentric study assessed retrospectively the usefulness of 18 F-FDG-PET in the staging of 31 patients with lymphocyte-predominant Hodgkin's disease (LPHD). FDG-PET and conventional explorations (CE) were performed for initial disease (n=25) or recurrence (n= 6). All the 68 involved sites were detected by PET including 5 extra-nodal lesions. Only 43 nodal sites (68%) and one splenic focus were detected by CE. PET changed staging in 9 patients (7 upstaged, 2 downstaged) and radiation fields in 3 patients. These results showed the potential role of PET in the staging of LPHD.

引用

页码：128 / 131

页数：4

共 20 条

[1] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[2] Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease [J].

Diehl, V ;

Sextro, M ;

Franklin, J ;

Hansmann, ML ;

Harris, N ;

Jaffe, E ;

Poppema, S ;

Harris, M ;

Franssila, K ;

van Krieken, J ;

Marafioti, T ;

Anagnostopoulos, I ;

Stein, H .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :776-783

[3]

Diehl V, 1999, HODGKIN'S DISEASE, P563

[4] Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial [J].

Ekstrand, BC ;

Lucas, JB ;

Horwitz, SM ;

Fan, Z ;

Breslin, S ;

Hoppe, RT ;

Natkunam, Y ;

Bartlett, NL ;

Horning, SJ .

BLOOD, 2003, 101 (11) :4285-4289

[5] Utility of FDG-PET scanning in lymphoma by WHO classification [J].

Elstrom, R ;

Guan, L ;

Baker, G ;

Nakhoda, K ;

Vergilio, JA ;

Zhuang, H ;

Pitsilos, S ;

Bagg, A ;

Downs, L ;

Mehrotra, A ;

Kim, S ;

Alavi, A ;

Schuster, SJ .

BLOOD, 2003, 101 (10) :3875-3876

[6]

Harris NL, 1999, SEMIN HEMATOL, V36, P220

[7]

HARRIS NL, 1994, BLOOD, V84, P1361

[8] Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake [J].

Hutchings, Martin ;

Loft, Annika ;

Hansen, Mads ;

Ralfkiaer, Elisabeth ;

Specht, Lena .

HEMATOLOGICAL ONCOLOGY, 2006, 24 (03) :146-150

[9]

Hutchings M, 2006, HAEMATOLOGICA, V91, P482

[10] Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL) [J].

Jerusalem, G ;

Beguin, Y ;

Najjar, F ;

Hustinx, R ;

Fassotte, MF ;

Rigo, P ;

Fillet, G .

ANNALS OF ONCOLOGY, 2001, 12 (06) :825-830

← 1 2 →